Clinical Trial

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Protocol Amendment History 4 changes
notable Primary completion moved earlier: 2027-04-01 -> 2026-04-14 2026-07-31
minor Completion moved earlier: 2027-12-31 -> 2026-12-31 2026-07-31
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-14
notable Enrollment reduced: 360 -> 227 participants 2026-04-14
Trial Details
NCT Number NCT04939090
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
Enrollment 227 participants
Start Date 2022-01-03
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30